Simple blood test may predict lung damage in autoimmune diseases

NCT ID NCT07393217

Not yet recruiting Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at a blood protein called FAP, which is linked to tissue scarring and inflammation. Researchers will measure FAP levels in people with rheumatoid arthritis and systemic sclerosis, as well as healthy volunteers, and compare them with standard tests and lung function. The goal is to see if FAP could become a useful blood marker for disease activity and lung involvement. Participation does not change usual medical care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test to help doctors monitor disease activity and lung involvement in rheumatoid arthritis and systemic sclerosis.
What could go wrong: This is an early observational study, not a treatment trial. The blood marker may not prove useful in real-world settings, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary fibrosis rheumatoid arthritis systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS (RA) SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Locations

Sohag University Hospital

Sohag, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.